UBQLN2 Gene Mutation Detection for ALS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating amyotrophic lateral sclerosis (ALS) are inadequate, as they fail to effectively identify the underlying causes of the disease, particularly for sporadic cases and those related to mutations in the UBQLN genes, which contribute to motor neuron degeneration and ALS/dementia.
Innovation Solution
Development of methods and compositions for detecting and targeting mutations in the UBQLN2 and UBQLN4 genes, including specific mutations such as c.1490C>A, c.1489C>T, c.1516C>A, c.1525C>T, and 202A>C, to identify ALS risk and provide therapeutic interventions by inhibiting or replacing mutant proteins and pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods are used for ALS, then diagnosis can be performed, but the underlying causes particularly for sporadic cases and UBQLN gene mutations cannot be effectively identified
Solution Approach 1:
The patent segments the diagnostic process by developing specific detection methods for different UBQLN gene mutations (UBQLN2, UBQLN4, UBQLN1) separately. Each mutation type is targeted with specific detection reagents and protocols, allowing precise identification of the underlying genetic cause while maintaining overall diagnostic accuracy.
2Measurement precision
If mutations in UBQLN genes are targeted for detection, then accurate diagnosis and risk assessment can be achieved, but the complexity of detection methods increases
Solution Approach 1:
The patent creates universal detection systems that can identify multiple UBQLN gene mutations through standardized protocols and reagents. The detection methods are designed to be multi-functional, capable of screening for various mutation types (c.1490C>A, c.1489C>T, c.1516C>A, c.1525C>T, 202A>C) using a unified approach, thereby reducing overall complexity.
Solution Approach 2:
The patent introduces specific detection reagents as intermediaries that facilitate the identification of UBQLN gene mutations. These reagents act as mediators between the genetic material and the detection system, simplifying the detection process by providing specific binding targets for each mutation type without requiring complex analytical procedures.
3Reliability
If therapeutic interventions targeting mutant UBQLN proteins are implemented, then disease progression can be halted or slowed, but the complexity of treatment approaches increases
Solution Approach 1:
The patent extracts and targets the specific mutant UBQLN proteins (UBQLN2, UBQLN4, UBQLN1) as separate therapeutic targets. By focusing on removing or neutralizing these specific mutant proteins rather than addressing the entire disease pathway, the treatment approach becomes more targeted and manageable despite the complexity of the underlying genetics.
Data Source
AI summary
Provided herein are compositions and methods for diagnosis, risk assessment, research, and therapy related to amyotrophic lateral sclerosis (ALS) and ALS-related disorders. In particular, the present invention relates to mutations in the UBQLN2 gene that cause dominantly inherited chromosome X-linked ALS and ALS/dementia.